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Pathological cardiac hypertrophy is associated with an increased risk of heart failure and cardiovascular mortality. Calcium
(Ca
2+) -regulated gene expression is essential for the induction of hypertrophy, but it is not known how myocytes distinguish
between the Ca
2+ signals that regulate contraction and those that lead to cardiac hypertrophy. We used in vitro neonatal rat
ventricular myocytes to perform an RNA interference (RNAi) screen for ion channels that mediate Ca
2+-dependent gene
expression in response to hypertrophic stimuli. We identified several ion channels that are linked to hypertrophic gene
expression, including transient receptor potential C3 (TrpC3). RNAi-mediated knockdown of TrpC3 decreases expression of
hypertrophy-associated genes such as the A- and B-type natriuretic peptides (ANP and BNP) in response to numerous
hypertrophic stimuli, while TrpC3 overexpression increases BNP expression. Furthermore, stimuli that induce hypertrophy
dramatically increase TrpC3 mRNA levels. Importantly, whereas TrpC3-knockdown strongly reduces gene expression associated
with hypertrophy, it has a negligible effect on cell size and on myocyte beating. These results suggest that Ca
2+ influx through
TrpC3 channels increases transcription of genes associated with hypertrophy but does not regulate the signaling pathways
that control cell size or contraction. Thus TrpC3 may represent an important therapeutic target for the treatment of cardiac
hypertrophy and heart failure.
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INTRODUCTION
Cardiac hypertrophy is associated with most chronic diseases of
the heart, including hypertension, valvular disease, ischemia, and
heart failure. While initially believed to be a beneficial adaptation
to stress, mounting clinical and experimental evidence indicate
that hypertrophy is maladaptive because it predisposes patients to
myocardial infarction, lethal arrhythmia, and heart failure
(reviewed in [1]). Therefore, cardiac hypertrophy is a major
therapeutic target for the treatment of heart disease [2].
Ca
2+ is a critical second messenger in the signaling pathways
leading to hypertrophy [3], and several Ca
2+-regulated phospha-
tases, kinases, and transcription factors play essential roles in
hypertrophy [4–7]. Because Ca
2+ regulates both myocyte contraction




transcription and hypertrophy [8]? One hypothesis is that specificity
is achieved by having the contractile and hypertrophy-inducing
machinery respond to different features of the intracellular Ca
2+
signal. According to this kinetic discrimination model, the signaling
cascades that lead to hypertrophy are activated when hormonal
stimulation changes the kinetics or the amplitude of the Ca
2+
transients that generate cardiac contraction [9]. Some support for
this model comes from observations that perturbations that increase
the amplitude, pulse duration, or frequency of the Ca
2+ elevations
that occur during beating all induce mild hypertrophy [10–14]. An
alternative hypothesis is that Ca
2+ signals that regulate hypertrophy
are spatially segregated from the Ca
2+ signals that regulate
contraction. One way to achieve the spatial separation of Ca
2+
signals involved in hypertrophy and contraction is by having
separate Ca
2+ channels linked to signaling proteins that regulate
either contraction or hypertrophy. The sarcolemmal Ca
2+ channel
involved in contraction, CaV1.2 (an L-type Ca
2+ channel), is
localized to the T-tubules, is closely apposed to the ryanodine
receptor RyR2 and other components involved in contraction, and
therefore generates localized Ca
2+ elevations that efficiently activate
the contractile apparatus. Thus far, however, the identity and
localization of the channels that regulate gene expression and induce
hypertrophy are not known.
Indirect evidence in favor of the spatial segregation model
comes from studies of G-protein coupled receptors (GPCRs) in the
heart. Cardiac hypertrophy is induced by activation of several
GPCRs, such as the a-adrenergic receptor, the angiotensin II
receptor, and the endothelin receptor (reviewed in [15]). GPCRs
stimulate a variety of ion channels by activating phospholipase C
(PLC) and other enzymes. Pharmacological data suggests that
myocytes possess GPCR-stimulated calcium currents that are
independent of CaV1.2 [16,17]. Furthermore, pharmacological
blockade of such currents has a greater effect on a variety of
hypertrophy phenotypes than does blockade of CaV1.2 [16].
These results suggest that GPCR-stimulated hypertrophy employs
ion channels distinct from CaV1.2.
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PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e802We report here our initial attempts to identify the ion channels
that regulate the induction of the gene expression program
associated with cardiac hypertrophy. We employed two unbiased
methods to identify ion channels that regulate cardiac hypertro-
phy: a real-time PCR-based assay for ion channels that are
expressed and dynamically regulated during hypertrophy, and an
RNA interference screen to search for channels that are necessary
for cardiac hypertrophy. Our search initially focused on the Group
1 transient receptor potential (Trp) superfamily of ion channels.
The Group 1 Trp channels, are a family of six-transmembrane-
domain cation channels with varying degrees of Ca
2+ selectivity
(reviewed in [18]) that include the TrpC, TrpV, TrpM, and TrpA
subfamilies. They share significant sequence similarity and wide
tissue distribution, and are only distantly related to the Group 2 Trp
channels(TrpMLandTrpPsubfamilies).TheGroup1Trpchannels
are good candidatesfor a roleinhypertrophy,asmany are expressed
in the heart [19,20] and previous work in other cell types has shown
that Trp channels are activated by many of the same GPCRs that
induce hypertrophy in cardiac myocytes [21–23].
Our screens identified TrpC3 as a mediator of cardiac
hypertrophy. TrpC3 mRNA levels are highly upregulated by
hypertrophic stimuli. In a1-adrenergic stimulated myocytes, TrpC3
knockdown decreases hypertrophic gene expression while TrpC3
overexpression augments the expression of hypertrophy marker
genes. However, TrpC3 knockdown does not affect cell size.
Intriguingly, the intracellular localization of TrpC3 channels is quite
distinctfromthatofCaV1.2andRyR2.TrpC3’slocalizationandlack
of effect on beat frequency and beating-associated calcium suggests
that it may produce calcium signals that are spatially independent of
those involved in contraction. These results identify an ion channel
that plays a prominent role in the induction of hypertrophy and
which may be a promising target for the treatment of heart disease.
RESULTS
RNAi screen identifies TrpC3 as an ion channel
involved in cardiac hypertrophy
To identify Ca
2+ channels that are important for the induction of
cardiac hypertrophy, we first measured the expression of candidate
ion channels in resting and hypertrophic cells. We stimulated
neonatal rat ventricular myocytes with the a1-adrenergic agonist
phenylephrine (PE) for 60 hours to induce hypertrophy. Stimula-
tion with PE led to a 69%616% increase in cell size (Fig. 1A
and1B) and to a 138620% increase in the activity of the promoter
of BNP (Fig. 1C), a gene critically involved in the pathology of
cardiac hypertrophy (we use the term ‘‘BNP’’ to refer to the gene
alternately called ‘‘pre-pro-BNP’’ or ‘‘Nppb’’). We next used real-
time RT-PCR to measure expression at the mRNA level of Group
1 Trp channels in both resting and hypertrophic cardiac myocytes.
We found that all the TrpC channels were significantly expressed
in ventricular myocytes and that several were dynamically
regulated during hypertrophy. One channel, TrpC3, was
significantly upregulated in hypertrophic myocytes (an increase
of 89%615%), whereas most of the other TrpC channels were
down-regulated by treatment with PE (Fig. 1D). These results show
that many Group1 Trp channels are expressed in myocytes and
are regulated by the signaling pathways that lead to hypertrophy.
Because many Group1 Trp channels are dynamically regulated
during hypertrophy, we next investigated which of these channels
are functionally important for this process. We designed an RNAi
screen using in vitro-diced double-stranded RNAs (d-siRNA) to
reduce the expression of the Group 1 Trp channels in rat
ventricular myocytes in vitro. We used d-siRNAs because this
approach has been reported to increase the efficiency of gene
suppression and to reduce off-target effects in other systems [24].
We introduced the d-siRNAs into cardiac myocytes along with
a reporter plasmid containing luciferase under the control of the
BNP promoter (BNP-Luc). We then stimulated the cells with PE
for 48 hours, after which we measured luciferase activity in cell
lysates using a 96-well automated luminometer. Before conducting
our full screen we performed a pilot experiment by transfecting
myocytes with BNP-Luc and d-siRNA targeting the CaV1.2 gene
or the bacterial gene LacZ. As expected, the d-siRNA against
LacZ had no effect on BNP-Luc, but the d-siRNA against CaV1.2
dramatically reduced BNP-Luc activity (Fig 1E). This is consistent
with previous results suggesting that Ca
2+ influx and contraction
mediated by CaV1.2 are necessary for the induction of cardiac
hypertrophy. In addition, this result provides proof-of-principle
that this assay is a viable method for identifying ion channels that
regulate cardiac hypertrophy.
We next extended our screen to cover all the Group 1 Trp
family members. We generated twenty d-siRNAs targeting all the
Group1 Trp channels, except TrpM1 and TrpM5 which could
not be amplified from myocyte mRNA. d-siRNAs targeting three
Trp family members, including TrpC3, strongly reduced the
expression of BNP-Luc. TrpC3 d-siRNA decreased the activity of
BNP-Luc by 64.6%69.8% (Fig. 1F). This decrease in BNP-Luc
expression was repeated in multiple experiments using different
concentrations of TrpC3 d-siRNA and different times of in-
cubation, suggesting that TrpC3 plays an important role in
activating the signaling cascades necessary for BNP production in
hypertrophic cardiac myocytes.
TrpC3 is necessary for hypertrophic gene expression
To verify that the effects of the TrpC3 d-siRNA pools are not
a consequence of off-target effects, we next used a different
technique for reducing the expression of TrpC3 in myocytes. We
generated lentiviruses encoding short-hairpin RNAs (shRNAs)
targeting TrpC3, as this method has a different set of off-target
effects than the d-siRNA pools used in the initial screen above. We
designed two shRNAs to target different sequences of TrpC3
(TrpC3-shRNA-1 and -2) and two shRNAs targeting the bacterial
gene LacZ as a negative control (LacZ-shRNA-1 and -2). We
packaged the shRNA vectors into lentiviral capsids, infected
ventricular myocytes, and cultured the cells for four days. We first
verified that the lentiviral shRNAs reduced the expression of
TrpC3 using real-time RT-PCR to measure endogenous TrpC3
transcripts. Compared to myocytes expressing shRNAs targeting
LacZ, myocytes expressing TrpC3-shRNA had significantly lower
TrpC3 mRNA levels (Fig 2A). As only ,65% of myocytes were
infected by the lentiviruses, the 52.4%64.0% decrease in
expression measured at the population level implies a 70%
knockdown of TrpC3 mRNA in individual infected cells. We next
measured the expression of endogenous BNP mRNA in the
infected cells. As shown in Figure 2B, myocytes expressing TrpC3-
shRNA have significantly lower levels of BNP mRNA relative to
myocytes expressing the control LacZ-shRNA. These experiments
demonstrate that two different TrpC3-shRNAs decrease BNP
expression and provide strong evidence that TrpC3 is necessary
for the expression of BNP in hypertrophic myocytes.
Cardiac hypertrophy can be induced by treating ventricular
myocytes with a wide variety of stimuli, ranging from GPCR
agonists like endothelin-1 (ET1) and PE to receptor tyrosine kinase
agonists such as epidermal growth factor (EGF). To determine
which types of stimuli require TrpC3 channels to induce
hypertrophy, we introduced the TrpC3 shRNAs and BNP-Luc
into cardiac myocytes and stimulated the cells with either PE,
ET1, or EGF. All of these agonists induced a significant induction
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a TrpC3-shRNA (Fig. 2C). Intriguingly, we found that TrpC3-
shRNA does not cause a significant decrease in BNP-luciferase
activity in cells that are not exposed to a hypertrophic stimulus
(Fig. 2C). These results suggest that TrpC3 is a common element
in multiple pathways leading to the induction of cardiac
hypertrophy and that it plays only a minor role in regulating
BNP levels in non-hypertrophic ventricular myocytes.
Figure 1. RNAi screen identifies TrpC3 as a mediator of hypertrophy-associated gene expression. (A) Increase in cell size in neonatal rat ventricular
myocytes stained with anti-a-actinin either untreated (left panel) or stimulated with 20 mM PE for 60 hours (right panel) to induce hypertrophy. (B)
Quantification of the two-dimensional cell area for the experiment described in A. Data are normalized to the mean of the cell-area for untreated cells.
For each condition, an average of n=28 cells were analyzed. (C) Luciferase expression in myocytes transfected with the BNP-luciferase (BNP-Luc)
reporter gene in the absence (left bar) or presence (right bar)o f2 0mM PE for 60 hours. BNP-luciferase activity is normalized to the activity of a co-
transfected plasmid constitutively expressing Renilla luciferase. n=4 biological replicates per condition. (D) Real-time RT-PCR measurements of TrpC
mRNA expression in untreated myocytes (grey bars) or myocytes stimulated with 20 mM PE for 60 hours (black bars). The data is normalized to the
mean of the untreated myocytes for each TrpC gene. Asterisks indicate a significant difference between untreated and PE-stimulated cells. n=4
measurements per condition. (E) Luciferase activity measured in myocytes transfected with BNP-Luc and d-siRNA targeting either the LacZ or CaV1.2
genes and stimulated with PE. CaV1.2 d-siRNA reduces the expression of the BNP-Luc reporter gene. n=6 biological replicates per condition. (D)
Ventricular myocytes were transfected with d-siRNAs targeting twenty of the twenty-two rat TRP channels along with BNP-Luc, stimulated with
20 mM PE for 48 hours and assayed luciferase activity. The luciferase activity of cells containing d-siRNAs targeting LacZ and the best hit, TrpC3 are
shown. n=12 biological replicates per condition. * indicates statistically significant difference compared to control, P,0.0001. ** indicates P,0.01.
For all bar graphs, data are represented as mean6SEM.
doi:10.1371/journal.pone.0000802.g001
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PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e802Figure 2. TrpC3 is necessary for hypertrophic gene expression. (A) Real-time RT-PCR measurement of TrpC3 mRNA in myocytes infected with
lentiviruses expressing shRNAs targeting either LacZ or TrpC3. Data is presented as percent decrease in expression compared to the mean expression
of myocytes expressing LacZ-shRNA#1. Asterisks indicate significant difference compared to LacZ-shRNA#1. n=4 per condition. (B) Real time RT-PCR
measurements of BNP mRNA levels in myocytes infected with the same lentiviruses as in A. TrpC3 shRNAs reduce the expression of endogenous BNP
mRNA. n=4 per condition. (C) Luciferase activity in myocytes transfected with BNP-Luc and plasmids expressing shRNAs targeting either TrpC3 or
LacZ. Cells were stimulated for 60 hours with 20 mM phenylephrine (PE), 100 nM endothelin-1 (ET1) or 150 ng/mL epidermal growth factor (EGF) to
induce hypertrophy. n=4 biological replicates per condition. (D) Luciferase expression in myocytes transfected with ANP-Luc and untreated or
stimulated with 20 mM PE. n=6 biological replicates per condition. (E) Myocytes transfected with plasmids expressing shRNAs targeting either LacZ
or TrpC3 were stimulated with 20 mM PE for 60 hours and then fixed and immunostained with an anti-ANP antibody. TrpC3 shRNA expression caused
a decrease in ANP staining. (F) Quantification of immunostained cells treated as in E. The integrated ANP-immunofluorescence intensity across the
two-dimensional projection of transfected cells was measured. Average n=31 cells per condition. In all panels, cells not expressing TrpC3-shRNA
were expressing a control shRNA against LacZ. * indicates statistically significant difference compared to control, P,0.01. ** indicates P,0.05. For all
bar graphs, data are represented as mean6SEM.
doi:10.1371/journal.pone.0000802.g002
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induction of not only BNP, but also of other genes associated
with hypertrophy. ANP plays an important role in the pathology
of cardiac hypertrophy and heart failure and is significantly
upregulated in hypertrophic myocytes. To determine if TrpC3 is
important for the expression of the ANP gene, we first measured
the activity of an ANP-Luciferase reporter gene (ANP-Luc) in
cells expressing TrpC3-shRNAs. While treatment with PE
increased the expression of ANP-Luc more than 6-fold in cells
expressing a control shRNA, PE caused only a 1.4-fold increase
in ANP-Luc expression in cells expressing TrpC3-shRNA
(Fig. 2D). To determine if TrpC3 is necessary for the expression
of endogenous ANP, we measured ANP protein levels using
quantitative immunocytochemistry with an anti-ANP antibody.
As expected, ANP protein levels increased upon PE stimulation,
but importantly, they were dramatically reduced in cells
expressing TrpC3-shRNA (Fig. 2E and 2F). Taken together these
results indicate that TrpC3 plays an important role in the
induction of both ANP and BNP, the two best-studied cardiac
hypertrophy genes.
Increased TrpC3 levels augment hypertrophic gene
expression
The experiments above suggest that TrpC3 expression is necessary
for the expression of both ANP and BNP, two genes that play an
important role in cardiac hypertrophy. To determine if the
expression of TrpC3 is sufficient for the production of ANP or BNP,
we overexpressed TrpC3 in cardiac myocytes and measured the
activation of the BNP-Luc reporter gene. Introduction of a plasmid
encoding human TrpC3 (hTrpC3) into cells led to the expression
of a protein of approximately 100 kDa, as expected (Fig. 3A, inset).
Expression of hTrpC3 in myocytes that were not stimulated with
PE had no effect on BNP promoter activity (Fig. 3A, comparing
columns 1 & 2). Thus increasing TrpC3 levels alone is not sufficient
to induce hypertrophic gene expression. However, in cells
stimulated with PE for 60 hours, overexpression of hTrpC3
caused a greater than two-fold increase in the expression of the
BNP-Luc reporter gene (Fig. 3B, comparing columns 3 & 4). These
results suggest that overexpression of TrpC3 strongly augments
BNP gene expression, but that this effect depends upon co-
stimulation with hypertrophic agonists such as PE.
We next employed hTrpC3 overexpression to determine if the
effects of the TrpC3-shRNAs on the expression of BNP are due to
the specific suppression of TrpC3 or are due to off-target effects.
We expressed hTrpC3, which is insensitive to rat TrpC3-shRNA,
in the presence of rat TrpC3-shRNA and subsequently measured
BNP-Luc activity. In the absence of hTrpC3, rat TrpC3-shRNA
caused a decrease in BNP-Luc activity (Fig. 3B, comparing columns
1 & 2). The reduction in BNP-Luc was smaller than we had
observed previously (Fig 2C), because we co-expressed the TrpC3-
shRNA with plasmids containing the CMV promoter. The CMV
promoter reduces the expression from other plasmid promoters
leading to reduced expression of TrpC3-shRNA. Importantly,
hTrpC3 expression rescued the effect of the rat TrpC3-shRNA on
BNP-Luc activity (Fig. 3B, comparing columns 3 & 4). This result
indicates that TrpC3-shRNA suppressed BNP-Luc by specifically
suppressing the expression of the endogenous rat TrpC3 and not
by suppressing other genes.
TrpC3 does not regulate cell size
One of the hallmarks of cardiac hypertrophy is an increase in
myocyte size. We therefore examined whether TrpC3 is necessary
for the increase in cell size associated with cardiac hypertrophy.
To do this, we developed a high-throughput assay of myocyte size
that would allow for rapid screening of the effects of knocking
down TrpC3 and other candidate hypertrophy genes identified in
our screens. Myocytes were transfected with plasmids that co-
express DsRed along with an shRNA that reduces the expression
of the target gene. After 48 hours of PE stimulation, the cells were
fixed and stained with anti-a-actinin antibody to distinguish
myocytes from other cell types in the cultures. Because myocytes
have low transfection efficiencies and variable size, we used an
automated microscope to collect images of large numbers of cells
(more than 1000 transfected myocytes per condition) to achieve
Figure 3. TrpC3 is sufficient for hypertrophy-associated gene expression. (A) Luciferase expression in myocytes co-transfected with BNP-Luc and
either a plasmid expressing hTrpC3 or the empty parent plasmid. Cells were stimulated for 60 hours with 20 mM phenylephrine (PE), or left un-
stimulated for the same period. Inset: Western blot analysis of HEK-293T cells transfected either with the parent plasmid or a plasmid expressing
hTrpC3 C-terminally tagged with Myc and 6x-His epitopes. The band shown is ,100 kDa. (B) Luciferase measurements of myocytes containing
plasmids encoding shRNAs targeting TrpC3 or LacZ and expression plasmids expressing hTrpC3 or an empty vector. hTrpC3 expression prevents the
reduction of BNP expression caused by TrpC3-shRNA expression. For both A and B, n=6 biological replicates per condition. * indicates statistically
significant difference compared to control, P,0.005. For all bar graphs, data are represented as mean6SEM.
doi:10.1371/journal.pone.0000802.g003
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cell size. We analyzed these images using an automated analysis
program that identified cells expressing DsRed, determined if they
were myocytes based on the intensity of anti-a-actinin staining,
and then measured cell size.
To determine the effects of TrpC3 on cell size, we used the
high-throughout cell size assay to measure the effects of PE
stimulation and TrpC3-shRNA. Stimulation with PE caused
a 20%61.1% increase in rat ventricular myocyte cell size, as
measured in more than 1000 cells per condition. The magnitude
of this effect is similar to what has been observed using other
techniques to measure increases in cell size. We next introduced
TrpC3-shRNA into these cells to reduce the expression of TrpC3.
Surprisingly, TrpC3-shRNA had no effect on the increase in cell
size caused by PE stimulation (Fig. 4A columns 2 vs 4), but did
cause a small increase in cell size in unstimulated cells. The lack of
effect of TrpC3-shRNA in PE-stimulated cells was confirmed by
using the manual method of cell size measurement on a smaller
number of myocytes (125 cells per condition) stimulated with or
without PE for 60 hours (Fig. 4B; representative myocytes
transfected with negative control shRNA and TrpC3-shRNA
are shown in Fig. 4C left and right panels, respectively). We repeated
these experiments using myocytes infected with lentiviruses
driving expression of TrpC3-shRNA and found no effect on the
increase in myocyte size after PE stimulation. Additionally, we
measured both cell size and endogenous ANP expression
simultaneously in the same PE-stimulated cells, and found that
TrpC3-shRNA decreased ANP expression (Fig. 2F), but had no
effect on cell size (Fig. 4D). Thus we conclude that while TrpC3
expression is necessary for the expression of ANP and BNP, it has
little or no effect on the increase in cell size associated with cardiac
hypertrophy.
Figure 4. Reduction of TrpC3 does not prevent the increase in cell size associated with hypertrophy. (A) Cell size measurement of ventricular
myocytes expressing either TrpC3 or a negative control shRNA and stimulated with 20 mM PE for 48 hours. Size is shown as percent increase
compared to the size of unstimulated myocytes expressing negative control shRNA (the left column). Cell size was measured using an automated
fluorescence microscope and analysis program. For each condition, n .1000 transfected myocytes analyzed. Columns 2–4 were each significantly
different than column 1,P ,0.001. Columns 2 and 4 (PE-stimulated myocytes expressing negative control shRNA or TrpC3-shRNA, respectively) are not
significantly different from each other. (B) The results in A were confirmed by using manual-measurements of myocyte cell size in cells stimulated
with 20 mM PE for 60 hours. Cells expressing TrpC3-shRNA were not significantly different in size than those expressing LacZ-shRNA. n=125 cells per
condition. (C) Examples of myocytes expressing negative control shRNA (left) and TrpC3-shRNA (right) used in the manual measurement of cell size.
Myocytes were stained with anti-a-actinin antibody (green), and cells that were expressing shRNAs are red. (D) Myocytes expressing LacZ- or TrpC3-
shRNAs were stimulated with 20 mM PE for 60 hours and then fixed, immunostained with anti-ANP antibody, and measured simultaneously for cell
size and ANP-immunofluorescence. TrpC3-shRNA had no effect on cell size (columns 2 and 3), but significantly decreased ANP expression (data
displayed in Fig. 2F). Average n=31 cells per condition. * indicates statistically significant difference compared to control, P,0.0001. For all bar
graphs, data are represented as mean6SEM.
doi:10.1371/journal.pone.0000802.g004
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2+ and PE-induced Ca
2+
elevation but not beating
Since gene expression associated with hypertrophy is regulated by
Ca
2+, we next sought to determine the role of TrpC3 in regulating
intracellular Ca
2+ ([Ca
2+]i). We began by examining the effect of
PE stimulation on [Ca
2+]i, because we had found that TrpC3
knockdown abrogated PE-induced gene expression. We loaded
uninfected myocytes with Fura-2 and imaged them on a digital-
imaging microscope to record [Ca
2+]i levels. To observe the effect
of PE on [Ca
2+]i independently of beating and of Ca
2+ influx
through CaV1.2, we pre-incubated and imaged the cells in media
containing the CaV1.2-blocker verapamil. Stimulation with
20 mM PE in media containing 2 mM Ca
2+ and verapamil
caused a transient [Ca
2+]i elevation that lasted approximately ten
seconds and a subsequent [Ca
2+]i decline that lasted at least
600 seconds (Fig. 5A, left panel). However, when the myocytes were
stimulated with PE in calcium-free media, the [Ca
2+]i elevation
was greatly diminished (Fig. 5A, comparing left and center panels).
This suggests that the PE-induced [Ca
2+]i elevation requires
extracellular calcium. We next compared the PE-induced [Ca
2+]i
elevation to the [Ca
2+]i rise produced by depolarizing myocytes.
Myocytes were incubated in media containing 2 mM Ca
2+ and
verapamil and stimulated with PE for 3 minutes, by which time
their [Ca
2+]i had reached a plateau. The myocytes were then
perfused with media containing 65 mM K
+ and no verapamil,
which induced a [Ca
2+]i elevation (Fig. 5A, right panel) that was
greater in amplitude and sustained much longer than the transient
[Ca
2+]i elevation triggered by PE. Thus the PE-induced [Ca
2+]i
elevation requires extracellular calcium and is relatively small in
magnitude compared to a depolarization-induced calcium rise.
We next examined the effect of TrpC3 knockdown on [Ca
2+]i
immediately before and after stimulation with PE. Myocytes
infected with lentiviruses encoding TrpC3-shRNA or a control
LacZ-shRNA were loaded with Fura-2 and imaged in media
containing 2 mM Ca
2+ and verapamil. Cells expressing TrpC3-
shRNA had a lower basal [Ca
2+]i level (Fig. 5B,C and D) than
LacZ-shRNA-expressing cells. Additionally, cells expressing
TrpC3-shRNA displayed a decreased amplitude of the [Ca
2+]i
spike following PE-stimulation, and a decreased difference
between peak and baseline [Ca
2+]i (Fig. 5B,C and D). This suggests
that TrpC3 regulates both basal [Ca
2+]i levels and also the
transient [Ca
2+]i elevation triggered by activation of a1-adrenergic
receptors.
Another important type of [Ca
2+]i elevation in ventricular
myocytes is the calcium rise that occurs with contraction. Previous
studies have shown that hypertrophic gene expression is de-
pendent on beat frequency and other aspects of beating-associated
calcium, which are controlled in part by CaV1.2 [14]. Therefore,
we assayed contraction frequency and measured [Ca
2+]i in
spontaneously beating myocytes to determine if TrpC3 affects
beat frequency or beating-associated calcium elevations. We first
measured intrinsic beat frequency in myocytes infected with
lentiviruses encoding TrpC3-shRNA or LacZ-shRNA. Myocytes
were plated at high density into multiple wells of a 96-well plate to
produce synchronous beating of nearly all cells in a well. The cells
were then subjected to 48 hours of PE stimulation to induce
hypertrophy. We used phase-contrast microscopy to measure the
contraction frequency of myocytes in 20 wells per condition, and
found that TrpC3-shRNA did not have a significant effect on beat
frequency (Fig 5E). We next measured [Ca
2+]i by high-speed
imaging (.80 Hz frame-rate) of Fluo4 calcium dye loaded into
spontaneously beating myocytes that had been stimulated with PE
for 72 hours. Compared to myocytes expressing LacZ-shRNA,
myocytes expressing TrpC3-shRNA did not have significantly
different beating-associated calcium dynamics (example traces
shown in Fig. 5F). Analyzing the calcium traces of 23 cells
expressing LacZ-shRNA and 23 cells expressing TrpC3-shRNA,
we did not find large differences in beat frequency (0.25 Hz for
LacZ-shRNA vs 0.27 Hz sec for TrpC3-shRNA; P=0.89), the
ratio of peak [Ca
2+]i to baseline [Ca
2+]i, (5.7 vs 6.1; P=0.51), or
the time from baseline to peak [Ca
2+]i (0.21 sec vs 0.20 sec;
P=0.92). There may, however, be a small difference between
LacZ- and TrpC3-shRNA expressing cells in the decay constant of
the [Ca
2+]i decline after a beat (0.67 sec vs 0.55 sec ; P=0.07).
Thus, while TrpC3 knockdown can decrease PE-induced [Ca
2+]i
elevations and decrease hypertrophy, it has little effect on
contraction and beating-associated calcium dynamics. This
suggests that the [Ca
2+]i signals generated by TrpC3 are
functionally uncoupled from the [Ca
2+]i elevations generated by
CaV1.2 which lead to muscle contraction.
TrpC3 localization is distinct from that of CaV1.2
One way in which Ca
2+ signals generated by TrpC3 channels
could be decoupled from those generated by CaV1.2 is by being
localized in different intracellular domains of myocytes. To
determine the intracellular localization of TrpC3 channels, we
used epifluorescence and total internal reflection (TIRF) micros-
copy to examine the distribution of tagged versions of TrpC3
channels in both unstimulated and hypertrophied myocytes. In the
majority of hypertrophied myocytes, TrpC3 C-terminally-tagged
with YFP (TrpC3-YFP) localized to puncta throughout the cell
(example shown in Fig. 6A, left panel). We co-stained these cells with
anti-a-actinin antibody, a marker of Z-lines, which are directly
apposed to the t-tubules. The co-staining (Fig. 6A, inset) revealed
little overlap between the localization of TrpC3 and that of
CaV1.2, which is mostly found in the t-tubules where it interacts
with the contractile machinery. In a subset of myocytes (example
shown in Fig. 6B), TrpC3-YFP was completely excluded from the
Z-line, and thus isolated from CaV1.2. The Trpc3-YFP punctate
pattern was also observed in all transfected myocytes that had not
undergone hypertrophy (Fig 3C, left panel), suggesting that the
punctate distribution is not greatly affected by hypertrophy. We
confirmed that a C-terminal YFP tag does not perturb the
localization of TrpC3 by expressing TrpC3 with an N-terminal
YFP tag and observing the same punctate distribution (Fig 3C, right
panel). Finally, we employed TIRF microscopy to image live
myocytes transfected with TrpC3-YFP. TIRF microscopy only
illuminates fluorophores within 0.2 mm of the coverglass. The
TIRF images revealed that in live myocytes TrpC3-YFP is in
discrete puncta ,200 nm from the cell surface (Fig. 6D, right panel).
Thus, under multiple imaging and stimulation conditions, TrpC3
channel localization is distinct from that of the CaV1.2 channels
that regulate beating.
DISCUSSION
In this study we used an unbiased screen to identify ion channels
that regulate cardiac hypertrophy. We designed a high-throughput
assay using cultured neonatal rat ventricular myocytes to screen an
RNAi library for calcium channels that regulate hypertrophy-
associated genes. Using this approach we identified several Group
1 Trp channels, including TrpC3, that play an important role in
the activation of genes associated with hypertrophy. This is the
first example of an RNAi-based screen for genes that mediate
cardiac hypertrophy and is a proof-of-principle for the utility of
this general approach. We extended this RNAi screen with two
other high-throughput assays for hypertrophy regulators: a real-
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2+]i and the PE-induced [Ca
2+]i elevation but does not affect beat frequency. (A) Mean [Ca
2+]i (normalized)
obtained by fura-2 measurements in uninfected myocytes. Myocytes maintained in media containing 2 mM Ca
2+ and the CaV1.2 blocker verapamil
were then stimulated with 20 mM PE (in addition to verapamil) in the presence of 2 mM extracellular Ca
2+ (left panel, n=58 cells) or 0 mM
extracellular Ca
2+ (center panel, n=101 cells) for the time indicated by the bar at the top of the panels.. Right panel (n=58 cells), myocytes previously
stimulated with PE and incubated in media containing 2 mM Ca
2+ and verapamil were then perfused with depolarizing media containing 65 mM K
+
and no verapamil. (B-C) [Ca
2+]i measurements in myocytes infected with lentiviruses expressing shRNAs targeting LacZ or TrpC3. Ratiometric fura-2
[Ca
2+]i measurements were performed on myocytes treated with verapamil and then stimulated with 20 mM PE (in addition to verapamil) for the time
indicated by the bar at the top of the panels. Representative traces from single myocytes are shown in B (top panel depicts examples of individual
cells expressing LacZ-shRNA; bottom panel, TrpC3-shRNA). Average traces are shown in C and represent the mean of 82 cells expressing LacZ-shRNA
(blue) and 117 cells expressing TrpC3-shRNA (red). (D) Mean baseline, peak, and peak minus baseline [Ca
2+]i of cells depicted in C. Average baseline
[Ca
2+]i sampled at 5 time-points before treatment with PE (columns 1 and 2), average amplitude of the [Ca
2+]i peak triggered by PE stimulation
(columns 3 and 4), and peak minus baseline calculated for each individual myocyte and then averaged across the population (columns 5 and 6). (E)
Spontaneous beat frequency of myocytes infected with lentiviruses expressing either LacZ- or TrpC3-shRNAs and stimulated for 48 hours with PE to
induce hypertrophy. Beat frequency was measured by phase contrast microscopy in 20 wells per condition. TrpC3 shRNAs had no effect on myocyte
beat frequency. (F) Fluo-4 measurements of [Ca
2+]i in spontaneously-beating myocytes expressing LacZ- or TrpC3-shRNAs and stimulated for
72 hours with PE. Calcium traces are displayed as Fluo-4 intensity values normalized by the minimum Fluo-4 value recorded from the given cell.
Displayed traces are from single representative myocytes expressing either LacZ-shRNA (top panel) or TrpC3-shRNA (bottom panel). Comparing Fluo-4
calcium traces for myocytes expressing LacZ-shRNA (n=23 cells) and TrpC3-shRNA (n=23 cells) did not detect any statistical difference in beat
frequency, peak:baseline ratio, or decay constants. * indicates statistically significant difference compared to control, P,0.0001. ** indicates P,0.005.
For all bar graphs and the traces in B, data are represented as mean6SEM.
doi:10.1371/journal.pone.0000802.g005
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during hypertrophy and an automated microscopy assay to
measure myocyte cell size. The widespread availability of
genome-wide RNAi libraries will make it possible to use our
screening methods to identify other genes that are required for the
development and maintenance of cardiac hypertrophy and which
may be novel targets for pharmaceutical development.
Our initial screens identified TrpC3 as a potent regulator of
hypertrophy-associated gene expression. Reducing the expression of
TrpC3 in a variety of ways reduced the expression of BNP and ANP
in response to activation of a1-adrenergic receptors. We employed
numerous controls for the specificity of RNAi knockdown of TrpC3,
including the use of two RNAi methods, two TrpC3-shRNAs, two
control LacZ-shRNAs, and successful rescue of TrpC3-shRNA’s
effect by overexpression of hTrpC3. Thus, while it is possible our
TrpC3 RNAi affects hypertrophy due to non-specific knockdown of
other targets (such as additional TrpCs), a great deal of evidence
suggests the TrpC3-RNAi results are specific.
Interestingly, TrpC3 is involved in the induction of hypertro-
phy-associated genes in response to a wide variety of stimuli. This
suggests that multiple receptors are linked to a common enzymatic
pathway that leads to the activation of TrpC3 and to transcription
of genes associated with cardiac hypertrophy. Notably, TrpC3
knockdown has a greater effect on BNP induction by PE than
ET1, perhaps suggesting other TrpCs or other calcium currents
may contribute differentially to different hypertrophic responses.
Nonetheless, our finding that TrpC3 is a common element in the
activation of gene expression in response to multiple stimuli
suggests that it might be a useful target for the development of
pharmacological blockers to treat heart disease.
Despite its key role in regulating hypertrophy-associated genes,
TrpC3 does not have a strong effect on myocyte beat frequency or
beating-associated calcium dynamics. Activation of TrpC3 by a1-
adrenergic receptors leads to [Ca
2+]i elevation, but this Ca
2+ does




2+ elevations generated by CaV1.2 channels that mediate muscle
contraction. How does Ca
2+ influx through these two channels
differentially activate signaling pathways leading to different cellular
events? One possibility is that each channel is associated with
Figure 6. TrpC3 channel localization is distinct from that of CaV1.2. (A–B) Epifluorescence microscopy images of fixed myocytes expressing TrpC3 C-
terminally tagged with YFP (TrpC3-YFP). Cells were stimulated for 48 hours with PE to induce hypertrophy. The majority of cells display a punctate
and perinuclear pattern of TrpC3-YFP (example shown in A, left panel). Co-staining with anti-a-actinin antibodies (A, right panel) reveals the
localization of the Z-lines, which are closely apposed to the t-tubules. Magnifying a merge of the TrpC3-YFP and anti-a-actinin images (A, inset) shows
little overlap between TrpC3-YFP puncta and the Z-lines. In some transfected myocytes, TrpC3-YFP puncta are completely excluded from the Z-lines
(example shown in B, inset). (C) TrpC3-YFP expressed in a serum-starved, un-hypertrophied myocyte (left panel) is also distributed in puncta. The same
punctate pattern is also observed in hypertrophied myocytes (right panel) expressing TrpC3 with an N-terminal YFP tag (YFP-TrpC3). (D) Live
myocytes co-transfected with CFP-Myr (a marker of the plasma membrane) and TrpC3-YFP were imaged by epifluorecence and total internal
reflection (TIRF) microscopy. CFP-Myr imaged by epifluorescence (left panel) illustrates the extent of the plasma membrane. A TIRF image of TrpC3-
YFP (right panel) indicates that, in live myocytes, tagged TrpC3 is found in puncta within 200 nm of the cell surface.
doi:10.1371/journal.pone.0000802.g006
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2+-dependent signaling proteins that are activated
by Ca
2+ influx through that channel. For example, CaV1.2 channels
are localized close to, and efficiently activate, RyR2 channels,
thereby triggering muscle contraction. In contrast, Ca
2+ influx
throughTrpC3apparentlydoesnotstronglyactivateRyR2channels
and therefore does not strongly affect beating. The observation that
TrpC3 is especially efficient at activating gene expression suggests
that it is associated with a different set of proteins than CaV1.2. This
isconsistentwith ourobservation that the intracellulardistribution of
TrpC3 is quite distinct from that of CaV1.2 and RyR2. The
dramatically different subcellular localization of TrpC3 and CaV1.2
may explain why Ca
2+ influx through TrpC3 channels does not
affect beating calcium but can activate signaling pathways leading to
the nucleus.
The finding that TrpC3 modulates hypertrophic gene expres-
sion but not beating does not imply that the calcium involved in
beating cannot also affect hypertrophy. Indeed, calcium influx
through CaV1.2 has been implicated in both beating and
hypertrophy. Previous reports have shown that pharmacological
blockade of CaV1.2 with dihydropyridines inhibits in vitro
hypertrophy [14], a result confirmed by our RNAi results with
CaV1.2 (Fig. 1E). Thus, it is possible that the calcium involved in
beating simultaneously regulates hypertrophy. According to the
kinetic discrimination model, calcium-activated signaling mole-
cules may convert changes in beating calcium dynamics into
changes in the expression of hypertrophy genes. Alternatively,
changes in beating calcium may activate hypertrophy through
mechanical stretch pathways. It must now be determined if TrpC3
and CaV1.2 activate hypertrophy by stimulating the same or
alternate downstream pathways.
A surprising finding of this study is that TrpC3 knockdown has
a strong effect on hypertrophic gene expression but does not
prevent the increase in cell size associated with hypertrophy. This
is unusual because nearly all genes that regulate hypertrophic gene
expression also regulate cell size. A few genes, such as the
transcription factor c-fos, however, affect hypertrophic gene
expression without affecting cell size [25], providing some
precedent for the effects of TrpC3. Future investigations of TrpC3
and c-fos may be thus useful in dissecting the pathways which
differentially control the multiple phenotypes of hypertrophy.
Additionally, because only a subset of the processes associated
hypertrophy are deleterious [1], TrpC3 may be a uniquely
interesting target for therapeutic intervention.
Therapeutic targeting of TrpC3 will likely require understand-
ing the interplay of TrpC3 with other Trp channels. Our RNAi
screen identified other Trp channels as regulators of hypertrophy,
which we are currently following up. Additionally, Trp channel
interactions may explain the curious result that TrpC3 slightly
increases cell size in the absence of hypertrophic stimuli. Perhaps
myocytes coordinately regulate the expression of TrpC3 and other
Trps, such that knockdown of TrpC3 in the absence of other
stimuli may modulate other Trp channels which regulate cell size.
Such coordinate regulation of multiple Trp genes has been
documented in other cell types [26]. In future work, it will be
essential to assay the expression of other Trp channels after
interventions targeting TrpC3 in the heart.
Our finding that TrpC3 is involved in regulating cardiac
hypertrophy agrees with three recent studies that appeared during
the preparation of this manuscript [27–29]. While those studies
identified a role for TrpC3 in inducing hypertrophy, our study
extends these initial findings in several important ways. First, we
identified TrpC3 from an unbiased screen for ion channel genes
that regulate cardiac hypertrophy, providing independent confir-
mation that TrpC3 mediates hypertrophy. Second, we have found
that TrpC3 regulates gene expression independently of beat
frequency. As TrpC3 is localized in a subcellular domain that is
different from the localization of CaV1.2, this provides strong
evidence for the idea that Ca
2+ influx through different ion
channels differentially regulates contraction and hypertrophy in
ventricular myocytes. Third, we show that TrpC3 is a common
element in the signal transduction cascades activated by several
agents that induce hypertrophy. Finally, we have found that
TrpC3 strongly regulates hypertrophy-associated gene expression
but has little effect on cell size, suggesting that these two pathways
are at least partly independent. Two of the other recent papers
found that overexpression of TrpC3 increased myocyte size
[27,28]. These studies indicate that some levels of TrpC3
perturbation, at least overexpression, are able to affect cell size.
However, our results suggest that even strong TrpC3 knockdown
has little effect on cell size while powerfully inhibiting hypertrophic
gene expression. Taken together, the experiments in this
manuscript add significantly to our understanding of the signaling
cascades that lead to cardiac hypertrophy and identify a new




We first compiled a database of the NCBI-curated sequences of
the rat Group 1 Trp channels. A list of the NCBI accession
numbers of the targeted genes is listed in Table S1. Diced-pools of
short interfering RNA (d-siRNA) were prepared as described
([24]). Briefly, we prepared cDNA from cultured neonatal rat
ventricular myocytes and rat E18 cortical neurons, using the
RNEasy Mini Kit (QIAgen) and First-Strand Synthesis Kit
(Invitrogen). For each Trp channel listed in Table S1, we
performed the following sequence to create d-siRNA. We made
a 400–500 base pair (bp) PCR product of the coding sequence of
the target gene, using as template a 1:1 mixture of the myocyte
and cortical neuron cDNA. We then made a 400–500 bp nested
PCR product from the initial PCR product. The nested PCR
primers all possessed a short leader sequence (GCG) followed by
the T7 promoter sequence (59-TAATACGACTCACTATAGG-
39) and 18–21 gene specific nucleotides. Primer sequences are
listed in Table S1. dsRNA was synthesized from the purified
nested PCR products using the MEGAScript High Yield
Transcription Kit (Ambion). dsRNA was treated with Dnase I at
37uC for 20 minutes, followed by denaturation at 75uC for
5 minutes and annealed at room temperature for 5 minutes to
produce a dsRNA product of 400–500 bp. Concentrations of
dsRNAs targeting the various Trp channels were normalized using
a UV spectrophotometer. Then we used the BLOCK-iT Dicer
RNAi Kit (Invitrogen) to perform the in vitro dicing reaction and
purify the 21–23 nucleotide d-siRNA pools. We were able to
successfully generate d-siRNA pools for all Group 1 Trp channel
members, except TrpM1 and TrpM5. We were never able to
obtain primary PCR products for TrpM1 and TrpM5 from the
myocyte and cortical neuron cDNA, despite testing three different
primer sets each. The repeated failure to PCR TrpM1 and TrpM5
suggests that these two genes are not expressed in myocytes and
therefore not necessary for testing by knockdown in myocytes.
Short-hairpin RNAs (shRNAs) were first expressed from the
lentiviral vector LentiLox 3.7 (LL37) [30], kindly provided by the
laboratory of L. Attardi. shRNAs were cloned into LL37 using the
method of Rubinson, et al. [30]. Briefly, we ordered a pair of
oligonucleotides (Integrated DNA Technologies, Corallville, IA)
that when annealed contained the shRNA coding sequence and
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made two LL37-based constructs which each expressed an shRNA
targeting different sequences within the rat TrpC3 coding sequence.
One TrpC3-shRNA target sequence (termed TrpC3-shRNA#1: 59-
GTTTGCTCGTTCCAAACTC-39) was chosen using the online
target selection tool of Dharmacon, Inc. (http://www.dharmacon.
com). The second TrpC3-shRNA target sequence (TrpC3-
shRNA#2: 59-GGCTGCGCATTGCCATAAA-39) was designed
as described [31]. The homologous sequence of TrpC3-shRNA#2
in Homo sapiens TrpC3 is 59-GGCGGCGCACTGCCAGAAA-39,
where the underlined basesrepresent internal mismatches compared
to the target sequence in rat TrpC3. The high number of internal
mismatches makes hTrpC3 resistant to TrpC3-shRNA#2, and thus
was used inRNAi rescue experiments. For negative controls, we also
constructed two LL37-based vectors expressing shRNAs targeting
two different sequences within the bacterial LacZ gene (LacZ-
shRNA#1: 59-GCACGTACCTGAATTTCGA -39;L a c Z -
shRNA#2: 59-TCGCTGATTTGTGTAGTCG-39). The same
shRNA target sequences were also cloned into the pSiren plasmid
(BD Biosciences), using BamHI and EcoRI cloning sites and the
oligonucleotide design method of the pSiren manual. For trans-
fection experiments, we alternately used either pSiren- or LL37-
based plasmids for testing the effects of shRNAs, and confirmed that
each set of plasmids both worked in several of the assays.
Comparisons between TrpC3-shRNA and negative control shRNA
were always done using the same parent plasmid. For data shown,
most luciferase assays employed LL37-based plasmids, while cell size
assays were done using pSiren-based constructs. For most experi-
ments, we employed TrpC3-shRNA#2 and LacZ-shRNA#2, but
we verified that the other shRNAs produced similar results in
multiple assays.
The BNP-Luciferase (BNP-Luc) construct, containing 1595 bp
of the rat genomic sequence upstream of the BNP gene controlling
the expression of firefly luciferase, was kindly provided by D.
Gardner ([32]). ANP-Luciferase (ANP-Luc), containing 638 bp of
the 59 upstream flanking sequence of the rat ANP gene controlling
firefly luciferase, was generously provided by C. Glembotski [33].
Human TrpC3 (hTrpC3) was cloned into pcDNA3 and kindly
provided by D. Clapham. We subcloned hTrpC3 into the pCR8/
GW/TOPO Gateway entry vector (Invitrogen). We then used the
Gateway LR clonase reaction to subclone hTrpC3 into two
Gateway-modified destination vectors, pCMV-XB-YFP and
pcDNA3.1-Myc-His-B, generating constructs containing either
TrpC3 with a C-terminal yellow fluorescent protein (YFP) tag, or
TrpC3 with a C-terminal tag containing the Myc and 6x-His
epitopes.
Cell culture, transfection, and infection
Ventricles were dissected from 1-day-old Sprague-Dawley rats
(Charles River), and dissociated using the neonatal rat NeoMyts
Kit (Cellutron, Highland Park, NJ). Cells were pre-plated for two
hours to separate adherent fibroblasts from non-adherent cardiac
myocytes. Myocytes were resuspended in DMEM containing 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 5 mM 5-bromo-2-
deoxyuridine (BrdU; Sigma), and penicillin/streptomycin (P/S)
and plated onto either gelatin-coated coverglasses or culture
dishes. Myocytes were plated at 700 cells/mm
2 for cell size assays,
and at 1100 cells/mm
2 for other experiments.
For transfection experiments, myocytes were plated in 24-well
plates that were either directly coated with gelatin (Sigma) or
contained gelatin-coated coverglasses. The media was changed to
OptiMEM (Invitrogen) 18–24 hours after plating the myocytes,
and myocytes were transfected using 2 ml Lipofectamine 2000 per
well. For luciferase experiments, 0.32 mg of firefly-luciferase
plasmid, 0.08 mg of the constitutively-expressing Renilla plasmid
pRLTK (Promega), and 0.4 mg of LL37- or pSiren-based plasmids
were transfected per well. For overexpression of TrpC3 in
luciferase assays, 0.8 mg of pcDNA3-based constructs were
transfected. Four hours after transfection, the media was replaced
with serum-starvation media containing DMEM, 2 mM gluta-
mine, 5 mM BrdU, and P/S. Twenty-four hours later, fresh
serum-starvation media was exchanged, and to designated cells we
added 20 mM (R)-(-)-Phenylephrine hydrochloride (PE) (Sigma) to
induce hypertrophy. A similar protocol was used for the induction
of hypertrophy using 100 nM endothelin-1 (ET1; Sigma) or
150 ng/mL epidermal growth factor (EGF; Upstate Cell Signal-
ing). Forty-eight to sixty hours later, myocytes were lysed for
luciferase assays. Myocytes were fixed for immunocytochemistry
and cell size assays 48 to 60 hours after initiation of PE stimulation.
Lentivirus was prepared as described ([34]). We performed
a relative titer of LL37-TrpC3-shRNAs and LL37-LacZ-shRNAs,
using myocyte infection and subsequent normalization of the
concentrated viruses to make ensure each viral stock had the same
number of infectious units per unit volume. For all experiments
employing infection, infection was performed 36 hours after
plating, adding virus sufficient to produce 60-70% infection and
4 mg/mL of polybrene (Sigma). Media was changed to plating
media 8 hours later. For real-time PCR measurement of gene
expression in infected myocytes, following infection the cells were
placed in fresh plating media for 4 days before lysis. For beat-
frequency measurements, cells were serum-starved (in 4:1
DMEM:M199+1% Nutridoma-SP [Roche]) for 24 hours after
completion of infection, stimulated with PE for 48 hours, and then
subjected to beat frequency measurement.
Real-time RT-PCR
Myocyte total RNA was isolated using the RNEasy Mini Kit
(QIAgen), and cDNA to be used as template in real-time PCR was
produced using the First-Strand Synthesis Kit (Invitrogen). Real-
time PCR primers were either based on published sequences or
designed using VectorNTI (Invitrogen). All real-time PCR primers
used are listed in Table S2. Real-time PCR was conducted using
the QuantiTect SYBR Green Kit (QIAgen) with a Stratagene
Mx3000P real-time PCR machine. The DDCt method was used to
calculate the relative difference of TrpC3 mRNA levels between
samples, normalizing with GAPDH levels. Each real-time PCR
reaction was repeated four times in parallel, and data are
presented as the mean of the GAPDH-normalized values, with
error bars representing standard error of the mean (SEM). At the
end of each real-time PCR run, a dissociation curve was measured
to show that only one PCR product was measured per reaction.
The PCR products for each reaction were then run on a 3%
agarose gel to confirm that the size of each product fit with the
predicted size (a 150–250 bp PCR product). For the TrpC3, BNP,
and GAPDH primer sets, the PCR products were also sent for
sequencing to confirm that the proper target had been amplified.
Luciferase assays
Myocytes were lysed using 1x Passive Lysis Buffer, and luciferase
reactions were performed using the Dual-Luciferase Reporter
Assay Kit (Promega). Reactions were performed and analyzed in
a Veritas Microplate 96-well Luminometer (Turner Biosystems).
The activity was measured both for firefly luciferase (encoded by
BNP-Luc and ANP-Luc) and for Renilla luciferase (encoded by
pRLTK). Renilla luciferase activity serves as an internal control.
Data are presented as ratios of firefly:Renilla activity. Each
condition was performed in at least six replicate wells, and each
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tive data shown in figures. Data are presented as mean plus SEM.
Cell size
Cells were fixed for 15 minutes at room temperature in PBS
containing 4% paraformaldehyde and 2% sucrose. Fixed cells
were permeabilized with 0.25% Triton-X-100 in PBS for
10 minutes, blocked in 3% BSA in PBS for 30 minutes, and then
incubated with anti-a-actinin antibody (Sigma, clone EA53) at
1:500 for 1 hour at room temperature. After washing, we
incubated with Alexa-488 goat anti-mouse secondary antibody
(Molecular Probes/Invitrogen) at 1:500 for 1 hour. Cells were
then stained with Hoechst dye (Molecular Probes). For high-
throughput cell size measurement, cells were plated in 24-well-
plate Primaria culture dishes (Becton Dickinson), and left in PBS
after Hoechst staining. For the traditional manually-measured cell
size assay, cells were plated on coverglass and after fixing and
staining were mounted on slides using AquaPolymount (Poly-
sciences, Warrington, PA).
For high-throughput cell size analysis, cells were imaged using
the 20x Objective of an Axon ImageXpress automated microscope
(Axon Instruments). Images were acquired using filtersets to detect
DsRed (expressed by pSiren), Alexa 488, and Hoechst. Six wells
were used per condition, and 42 sites were imaged per well. An
ImageXpress analysis script was composed that found and drew
a border around transfected cells based on DsRed intensity, gated
out transfected non-myocytes based on low intensity of Alexa 488
signal, and other artifacts (e.g., dead cells) were excluded using
properties of all three filterset images. The script then output cell
area, which after stringent gating, yielded approximately 1000 cell
size measurements per condition. Data are presented as mean plus
SEM.
To confirm the high-throughput cell size analysis, we used the
traditional manually-measured cell size assay on cells transfected
and treated identically as those in the high-throughput assay.
Imaging was done by hand using a Nikon Eclipse TE2000-U
epifluorescence microscope, 20x objective. Cell outlines were
traced by hand and area was measured in OpenLab (Improvision,
Lexington, MA). At least 150 cells were traced per condition. We
also performed cell size analysis using the manual method on
lentivirally-infected cells (data not shown).
Beat Frequency Assay and Calcium Imaging
Myocytes were plated in 96 well plates and infected and cultured
as described above. After 48 hours of PE stimulation, myocytes
were taken out of 37uC incubator, and placed in Hanks9 Balanced
Salt Solution (HBSS), supplemented with 0.1 % BSA, 1%
Nutridoma-SP, and 20 mM PE, so that pH would remain stable
but other stimulation conditions would resemble those in other
experiments. Cells were imaged using phase-contrast and a 20x
objective on a Nikon Eclipse TE2000-U to observe the
synchronous beating of cells in each well. The number of beats
in a 90 second period was counted manually. Data presented as
mean plus SEM for 20 wells per condition.
For calcium imaging of beating-associated calcium, myocytes
were cultured similarly as for the beat frequency assay, except they
were cultured on 15 mm coverglass. The cells were then incubated
in 2 mM Fluo-4-AM (Molecular Probes) in HBSS for 20 minutes
at room temperature, washed twice in PBS, and then loaded into
a closed perfusion chamber in room-temperature HBSS supple-
mented with 0.1 % BSA, 1% Nutridoma-SP, and 20 mM PE. Cells
were imaged using a 60x objective on a Nikon Eclipse TE2000-U.
Each cell was imaged for 25 seconds, at a frame rate of ,80 Hz.
Raw Fluo-4 traces were processed by background subtraction and
then correction for photobleaching by dividing by an single-
exponential curve fit to our experimentally-measured decay of
Fluo-4 in each cell.
For calcium imaging of acute PE stimulation, the myocytes were
infected with LL37-based lentiviruses two days after plating, or
mock-infected, and then incubated 24 to 48 hours in serum-free
media supplemented with Nutridoma-SP. The cells were then
incubated in 2 mM fura-2-AM (Molecular Probes) in HBSS+0.1%
BSA for 25 minutes at 37uC, washed twice in PBS, and then
incubated in fresh HBSS for 10 minutes at 37uC. Cells were
subsequently loaded into a closed perfusion chamber in room-
temperature HBSS+containing 0.1% BSA and 10 mM of the
CaV1.2-blocker verapamil. For uninfected cells, the cells were
imaged for 100 seconds, after which the appropriate stimulus was
added: 20 mMP E +verapamil or 20 mMP E +verapamil+2m M
EGTA in calcium-free media. The cells stimulated in 2 mM Ca2+
solution were then stimulated 3 minutes later with media
containing 2 mM Ca
2+ and 65 mM K
+ without verapamil, in
order to determine the response to depolarization. For infected
cells, after 100 seconds of imaging, HBSS containing 10 mM
verapamil and 20 mM PE was added. Pairs of images (using
excitation wavelengths of 340 nm and 380 nm) were taken every
5 seconds for a total duration of 700 seconds. Data were
converted into ratios of the images taken with excitation
wavelengths of 340 nm and 380 nm; these ratios are termed
F340/F380. Ratio images were then converted to absolute calcium
levels using a calcium calibration kit (Molecular Probes). Data are
presented as mean of all cells measured plus SEM.
Immunocytochemistry and TIRF imaging
Cells were fixed and permeabilized as described for cell size assays.
Anti-a-actinin (Sigma) was used at 1:500 and stained with 1:500
goat anti-mouse Alex 594. Cells were imaged on a Nikon Eclipse
TE2000-U epifluorescence microscope, 60x objective.
For the ANP-immunocytochemistry assay, myocytes were
transfected with LL37-based plasmids and stimulated as described
above. After fixation and permeabilization, cells were incubated
overnight at 4uC with anti-ANP (Peninsula Labs, 1:200) and anti-
a-actinin (1:500) antibodies, and subsequently stained with goat
anti-rabbit Alexa 594 and goat anti-mouse Marina Blue secondary
antibodies (Molecular Probes). Cells were imaged with the
aforementioned microscope, 20x objective. The ANP levels of
each cell were taken as the product of mean ANP-fluorescence per
pixel multiplied by the area of the two-dimensional projection of
the cell. Myocytes from three separate wells were used for each
experiment, and data is presented as the mean ANP level for each
condition, with error bars depicting SEM.
For TIRF imaging, cells were plated onto 15 mm coverglasses
and transfected with the relevant constructs. CFP-Myr encodes
CFP with a myristolation tag, and is used to indicate the plasma
membrane in live cells. Myocytes co-transfected with CFP-Myr
and TrpC3-YFP were put into a closed perfusion chamber
containing room temperature HBSS+0.1% BSA. The cells were
imaged with a 60x TIRF objective, imaging CFP in epifluores-
cence mode and YFP in TIRF mode.
Western blot analysis
Human embryonic kidney 293 cells (HEK293) were transfected
with hTrpcc3-MycHis using calcium phosphate. Two days after
transfection, cells were lysed in lysis buffer (150 mM NaCl,
50 mM HEPES pH 7.5, 1% Triton-X-100, 0.4% sodium dodecyl
sulfate [SDS]), resolved on an SDS-polyacrylamide gel, transferred
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Myc primary antibody (Upstate Cell Signaling) followed by anti-
mouse IgG conjugated to horseradish peroxidase (Pierce).
Compared to untransfected HEK293 lysate, the transfected cells
only displayed a single band that ran at ,100 kDa.
Statistical Analyses
Statistical tests were performed using Prism (GraphPad, San
Diego, CA). For experiments involving three or more potential
comparisons, we used one-way ANOVA followed by Dunnett’s
post-test. For experiments in which only one comparison was
meaningful, unpaired one-tailed t-tests were employed.
SUPPORTING INFORMATION
Table S1 PCR primers used for the production of the d-siRNA
library.
Found at: doi:10.1371/journal.pone.0000802.s001 (0.08 MB
DOC)
Table S2 PCR primers used in real-time RT-PCR
Found at: doi:10.1371/journal.pone.0000802.s002 (0.03 MB
DOC)
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